ArticleOphthalmic plastic and reconstructive surgery
"Real-Life" Utility of the Graves' Ophthalmopathy-Quality of Life in a Multidisciplinary Thyroid Eye Disease Service.
Article in Ophthalmic plastic and reconstructive surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to describe the correlation of demographic and clinical factors with the Graves' ophthalmopathy-quality of life (GO-QOL) visual function (VF) and appearance (A) scores in a cohort attending a metropolitan multidisciplinary thyroid eye disease (TED) service.
methodsThis is a cross-sectional retrospective study of 152 consecutive TED patients who completed the GO-QOL questionnaire. Clinical parameters, including endocrine diagnosis and status, TED activity and severity, Gorman diplopia score, and TED treatments were recorded at the time of completing each questionnaire and retrospectively analyzed.
resultsA total of 257 GO-QOL questionnaires were completed over 32 months, with 59 patients providing sequential responses. The mean age was 50.0 ± 13.1 years, 77.0% (117/152) were female and 52.0% (79/152) were Caucasian. Graves' disease was present in 86.2% (131/152) of participants, and 91.4% (139/152) were euthyroid at the time of the questionnaire. The mean time since TED onset was 2.5 years (range: 0.25-180 months). The mean ± standard deviation GO-QOL scores in the mild, moderate-to-severe, and sight-threatening disease cohorts for VF were 92.2 ± 15.2, 70.9 ± 28.6, and 56.6 ± 29.6, respectively, and for A were 79.1 ± 22.3, 48.2 ± 29.7, and 66.1 ± 35.3, respectively. VF and A scores were inversely correlated with clinical activity scores. Both scores improved postimmunosuppression but only A scores improved following decompression and rehabilitation surgery. Females and younger patients had lower A but not VF scores. East Asians and Caucasians had higher VF and A scores than African-Caribbeans.
conclusionThe GO-QOL's granularity highlights the diverse functional and psychosocial experiences of TED patients, underscoring the need to integrate this valuable but underutilized tool into routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.